DiagnaMed expands its product range with an AI platform for drug and clinical research

Leveraging proprietary EEG data from past and future research studies with BRAIN AGE® Brain Health AI

Accelerating the development of clinical trials and discovering potential new treatments for neurological, psychiatric and infectious diseases

TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, announces that it is expanding the use of its novel BRAIN AGE® Brain Health AI Platform (“BRAIN AGE®”) by leveraging its electroencephalogram (“EEG”) data from research studies and future data collections and applying it to build a potential AI platform for drug discovery and clinical research. EEG provides a real-time display of brainwave activity in different brain regions and can measure the effects of drugs on the brain. BRAIN AGE® has the potential to accelerate patient recruitment for clinical trials, data analysis, go/no-go decisions for drug development and new treatment options for neurological, psychiatric and infectious diseases.

BRAIN AGE® Brain Health AI estimates brain age by recording brainwave activity from multiple brain regions and calculating the data using a proprietary machine learning model. Certain drugs acting on the brain can produce a consistent EEG effect and produce models useful for developing new drug analogues¹ and potential drug repurposing ideas. By studying the effects of drugs on the brain via EEG, researchers can classify and identify drugs based on their mechanism of action on brain activity.²

Clinical validation of BRAIN AGE® AI platform for brain health

BRAIN AGE® Brain Health AI can assess whether a brain is aging faster or slower than typical in healthy individuals. Brain age is estimated by collecting data on brain neural activity using an inexpensive and easy-to-use electroencephalogram headset and calculating the data using a proprietary machine learning model. In addition, BRAIN AGE® Brain Health AI can assess whether a person has a healthy brain or is in the early stages of cognitive decline. Brain health is evaluated through a clinically validated assessment of brain resilience, vulnerability, and performance functions. Individuals can access personalized diagnostics and interventions such as medications or lifestyle changes that can help slow the development or progression of cognitive decline.

In a first peer-reviewed article in Limits of neuroergonomicswith the title “Estimating brain age using a low-cost EEG headset: effectiveness and implications for large-scale screening and brain optimization.”³BRAIN AGE®, as announced in a press release from Drexel University, Prof. Kounios was quoted on the clinical potential of BRAIN AGE®: “It can be used as a relatively inexpensive method to screen large numbers of people for susceptibility to age-related diseases. And because of the low cost, a person can be screened at regular intervals to detect changes over time,” Kounios said. “This can help test the effectiveness of drugs and other interventions. And healthy people could use this technique to test the effects of lifestyle changes as part of an overall strategy to optimize brain performance.”⁴

About DiagnaMed

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a healthcare technology company focused on brain health using AI. DiagnaMed markets the BRAIN AGE® Brain Health AI Platform, a world-first AI solution for consumer brain health and wellness that estimates brain age and provides a brain health score. Visit DiagnaMed.com.

For further information please contact:

Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Phone: 416-800-2684
Email: [email protected]
Website: www.diagnamed.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed and accepts responsibility for the adequacy or accuracy of this release.

Warning

Certain statements in this press release are forward-looking, including statements regarding future plans and other matters. Forward-looking statements are statements that are not purely historical in nature, including statements regarding beliefs, plans, expectations or intentions regarding the future. Such information generally can be identified by the use of forward-looking phrases such as “will,” “could,” “expect,” “might,” “may,” “estimate,” “anticipate,” “intend,” “believe,” “project,” “goals” and “continue” or the negative of these or similar variations. The reader is cautioned that assumptions used in preparing forward-looking information may prove to be incorrect. Events or circumstances could cause actual results to differ materially from those projected due to numerous known and unknown risks, uncertainties and other factors, many of which are beyond the Company's control, including, but not limited to, business, economic and capital market conditions, the ability to manage operating expenses and dependence on key personnel. Such statements and information are based on numerous assumptions regarding current and future business strategies and the environment in which the Company will operate in the future, expected costs and ability to achieve objectives. Factors that could cause actual results to differ materially from those contained in forward-looking statements include continued availability of capital and financing, litigation, failure by contractors to fulfill contractual obligations, loss of key employees and consultants and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the heading “Risk Factors” in the Company's Management's Discussion and Analysis for the three and six months ended March 31, 2024 (“MD&A”), dated May 29, 2024, which is available under the Company's profile at. www.sedarplus.ca. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on forward-looking information. The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, the Company disclaims any intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

Footnotes:

1. Bewernitz M, Derendorf H. Electroencephalogram-based pharmacodynamic measures: a review. Int J Clin Pharmacol Ther. 2012 Mar;50(3):162-84. doi: 10.5414/cp201484. PMID: 22373830; PMCID: PMC3637024.

2. Kalitin, Konstantin Y., et al. “Deep learning analysis of intracranial EEG for detection of drug effects and mechanisms of action.” arXiv preprint arXiv:2009.12984 (2020).

3. Kounios John, Fleck Jessica I., Zhang Fengqing, Oh Yongtaek. Estimating brain age using a low-cost EEG headset: effectiveness and implications for large-scale screening and brain optimization. Frontiers in Neuroergonomics. 2024; Volume 5. DOI=10.3389/fnrgo.2024.1340732.